Fellowship · St. Louis, MO
Sponsored by SSM Health/Saint Louis University School of Medicine
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Naim Alkhouri
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) · 2023 · 2,087 citations · Brent Tetri
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment.
The lancet. Diabetes & endocrinology · 2025 · 317 citations · Brent Tetri
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 424 citations · Hisham Hussan
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
The New England journal of medicine · 2024 · 417 citations · Naim Alkhouri
Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050.
JAMA network open · 2025 · 195 citations · Naim Alkhouri
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
The New England journal of medicine · 2021 · 954 citations · Brent Tetri
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) · 2024 · 320 citations · Brent Tetri